An oncologist observed that some ITP patients treated with rilzabrutinib or yanalumab experienced an unexpected side benefit: improvement in their seasonal allergy symptoms. This suggests these autoimmune-targeted therapies may have broader effects on immune dysregulation beyond just ITP.

Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

The target platelet count for ITP patients should be tailored to their lifestyle, bleeding history, and quality of life goals. A normal platelet count is not necessary, and different thresholds are appropriate for different patients (e.g., someone planning a ski trip versus a sedentary individual).

In the VEHAT-two trial for ITP, 8% of patients receiving a placebo infusion experienced an infusion reaction. This surprising finding underscores the necessity of placebo-controlled studies to differentiate true drug-related adverse events from effects caused by the procedure or patient expectation.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

An expert argues the path to curing metastatic cancer may mirror pediatric ALL's history: combining all highly active drugs upfront. Instead of sequencing treatments after failure, the focus should be on powerful initial regimens that eradicate cancer, even if it means higher initial toxicity.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

Named after the two-faced god Janus, yanalumab has a dual mechanism. It acts as a highly potent B-cell depleter while also blocking the BAF receptor pathway, which is critical for auto-reactive B-cell survival. This offers potential for deep, lasting, treatment-free remission.